Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis

J Cyst Fibros. 2011 Dec;10(6):470-6. doi: 10.1016/j.jcf.2011.07.007. Epub 2011 Aug 16.


Background: The aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF.

Methods: Patients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of -1 or less were randomised to receive risedronate 35 mg weekly or placebo, and calcium (1g)+vitamin D(3) (800IU).

Results: At baseline, BMD Z-scores in the risedronate (n=17) and placebo (n=19) groups were similar. By 24 months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. After 24 months treatment, the mean difference (95% CI) in change in LS, TH and FN BMD between the risedronate vs placebo groups was 4.3% (0.4, 8.2) p=0.03; 4.0% (-0.5, 8.6) p=0.08; and 2.4% (-3.5, 8.2) p=0.41.

Conclusions: After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Bone Density / drug effects*
  • Bone Density Conservation Agents / administration & dosage*
  • Bone Density Conservation Agents / pharmacology
  • Cystic Fibrosis*
  • Drug Administration Schedule
  • Etidronic Acid / administration & dosage
  • Etidronic Acid / analogs & derivatives*
  • Etidronic Acid / pharmacology
  • Female
  • Humans
  • Male
  • Risedronic Acid
  • Single-Blind Method


  • Bone Density Conservation Agents
  • Risedronic Acid
  • Etidronic Acid